Close

Anti-CD99 (MIC2/1495R) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-CQ0323)


All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

The vector of anti-CD99 chimeric antigen receptor (CAR) is constructed for the engineering of T cell to target CD99. The T cells are genetically modified through transduction with a lentiviral vector expressing scFv of anti-CD99 antibody linked to 4-1BB (CD137) and CD3ζ signaling domains. And the vector product was designed for the treatment of Glioma.

Specific Inquiry

  • Size:
  • Marker:
  • Form:
  Add to Cart

Details

  • Target
  • CD99
  • Targeting Cell Type
  • T cell
  • Targeting Diseases
  • Glioma
  • Generation
  • Second
  • Vector Name
  • pCDCAR1
  • Vector Length
  • ~8kb
  • Vector Type
  • Lentiviral vector
  • Receptor Construction
  • scFv-41BB-CD3ζ
  • Discription of Signaling Cassetes
  • 41BB
    CD137 (also known as 4-1BB) is a surface co-stimulatory glycoprotein originally described as present on activated T lymphocytes, which belongs to the tumor necrosis factor (TNF) receptor superfamily. It is expressed mainly on activated CD4+ and CD8+ T cells, and binds to a high-affinity ligand (4-1BBL) expressed on several antigen-presenting cells such as macrophages and activated B cells. On the basis of preclinical observation, this molecule can promote the persistence of antigen-specific and antigen-nonspecific chimeric antigen receptor T-cells to significantly increases antitumor activity.
    CD3ζ
    CD3ζ, also known as T-cell receptor zeta, which together with T-cell receptor and CD3γ, δ, ε chain, forms the TCR-CD3 complex. ζ was expressed independently from the complex. The zeta chain plays an important role in coupling antigen recognition to several intracellular signal-transduction pathways. CD3-zeta, which contains 3 ITAMs, is the most commonly used endodomain component of CARs. It transmits an activation signal to the T cell after antigen is bound. CD3-zeta may not provide a fully competent activation signal and additional co-stimulatory signaling is needed. For example, chimeric CD28 and OX40 can be used with CD3-zeta to transmit a proliferative/survival signal, or all three can be used together.

Target

  • Clone
  • MIC2/1495R
  • Host
  • Rabbit
  • Target Species
  • Human
  • Gene Name
  • CD99
  • Synonyms
  • MIC2; HBA71; MIC2X; MIC2Y; MSK5X

Customize Your CAR Products

Cannot find the desired product? Don't worry, just try our online CAR and CAR cell customizing system, which offers full options to meet all unique needs, including but not limited to conventional or unconventional CAR constructs, as well as a variety of vectors and cells. The customization process can be completed with just a few simple clicks, please feel free to try it out.
CAR and CAR Cell Customizing System
  • Published Data
Complete CAR data FCM

Fig.1 Expansion of CAR-T cell.

CAR Construction : 12E7-CD28-41BB-CD3ζ Latest CAR Construction

Fig.1 Expansion of CAR-T cell.

Expansion fold change of CAR positive cells for 12 days.

Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5.

Complete CAR data Cyt

Fig.2 Anti-CD99 CAR T cells showed specifically target the T-ALL cell lines and primary cells but with minimal killing of normal blood cells.

CAR Construction : 12E7-CD28-41BB-CD3ζ Latest CAR Construction

Fig.2 Anti-CD99 CAR T cells showed specifically target the T-ALL cell lines and primary cells but with minimal killing of normal blood cells.

In vitro cytotoxic activity of anti-CD99 CAR T cells against different normal blood cells (top picture), T-ALL cell lines (Jurkat/ CUTLL-1) (medium picture) and T-ALL patients' blasts (bottom picture).

Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5.

Complete CAR data BI

Fig.3 Efcacy and specifcity of anti-CD99 CAR T cells in cell line-derived xenograft models of T-ALL.

CAR Construction : 12E7-CD28-41BB-CD3ζ Latest CAR Construction

Fig.3 Efcacy and specifcity of anti-CD99 CAR T cells in cell line-derived xenograft models of T-ALL.

Tumor progression was monitored using bioluminescent imaging.

Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5.

Complete CAR data FuncS

Fig.4 Kaplan-Meier survival curves.

CAR Construction : 12E7-CD28-41BB-CD3ζ Latest CAR Construction

Fig.4 Kaplan-Meier survival curves.

Kaplan-Meier survival curves of Jurkat cell line-derived xenograft mice, MOLT-4 cell line-derived xenograft mice,nonETP ALL patient-derived xenograft mice and ETP ALL mice treated with T cells or anti-CD99 CAR T cells.

Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5.

CAR scFv data BLI

Fig.5 Binding kinetics of anti-CD99 scFv with CD99 protein.

CAR Construction : Latest CAR Construction

Fig.5 Binding kinetics of anti-CD99 scFv with CD99 protein.

Analysis of the interaction between the 12E7 scFv and CD99 protein using BLItz biolayer interferometry

Shi, J., Zhang, Z., Cen, H., Wu, H., Zhang, S., Liu, J., ... & Zhu, H. (2021). CAR T cells targeting CD99 as an approach to eradicate T-cell acute lymphoblastic leukemia without normal blood cells toxicity. Journal of hematology & oncology, 14(1), 1-5.

More Published Data More Published Data

Customer Reviews and Q&As

There are currently no customer reviews or questions for Anti-CD99 (MIC2/1495R) h(41BB-CD3ζ) CAR, pCDCAR1 (CAR-CQ0323). Click the button below to contact us or submit your feedback about this product.

For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.

Related Products

Online Inquiry

For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Key Updates
Newsletter NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER
New Solution NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION
NOVEL SOLUTION NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY
NEW TECHNOLOGY NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION
Receive our latest news and insights.